The DOI matches its Crossref record; 243 of the 243 references it cites were found in a registry or an index.
Display technologies: Application for the discovery of drug and gene delivery agents☆
Open accessAbstract
Recognition of molecular diversity of cell surface proteomes in disease is essential for the development of targeted therapies. Progress in targeted therapeutics requires establishing effective approaches for high-throughput identification of agents specific for clinically relevant cell surface markers. Over the past decade, a number of platform strategies have been developed to screen polypeptide libraries for ligands targeting receptors selectively expressed in the context of various cell surface proteomes. Streamlined procedures for identification of ligand-receptor pairs that could serve as targets in disease diagnosis, profiling, imaging and therapy have relied on the display technologies, in which polypeptides with desired binding profiles can be serially selected, in a process called biopanning, based on their physical linkage with the encoding nucleic acid. These technologies include virus/phage display, cell display, ribosomal display, mRNA display and covalent DNA display (CDT), with phage display being by far the most utilized. The scope of this review is the recent advancements in the display technologies with a particular emphasis on molecular mapping of cell surface proteomes with peptide phage display. Prospective applications of targeted compounds derived from display libraries in the discovery of targeted drugs and gene therapy vectors are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Initial sequencing and analysis of the human genome
International Human Genome Sequencing Consortium, Whitehead Institute for Biomedical Research, C. F. G. R., Lander, E. S., Linton, L. M., Birren, B., Nusbaum, C., Zody, M. C., Baldwin, J., Devon, K., Dewar, K., et al. (2001) · Nature · doi:10.1038/35057062 · Cited by 24,216
The sequence of the human genome
Venter, J. C., Adams, M. D., Myers, E. W., Li, P. W., Mural, R. J., Sutton, G. G., Smith, H. O., Yandell, M., Evans, C. A., Holt, R. A., et al. (2001) · Science · doi:10.1126/science.1058040 · Cited by 13,909
Massagué, J. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.753 · Cited by 7,556
Pushko, P., Pumpens, P., & Grens, E. (2013) · Intervirology · doi:10.1159/000346773 · Cited by 5,950
Cancer genes and the pathways they control
Vogelstein, B., & Kinzler, K. W. (2004) · Nature Medicine · doi:10.1038/nm1087 · Cited by 4,249
Smith, G. P. (1985) · Science · doi:10.1126/science.4001944 · Cited by 4,143
Monks, A., Scudiero, D., Skehan, P., Shoemaker, R., Paull, K., Vistica, D., Hose, C., Langley, J., Cronise, P., Vaigro-Wolff, A., et al. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.11.757 · Cited by 3,289
Bongartz, T., Sutton, A. J., Sweeting, M. J., Buchan, I., Matteson, E. L., & Montori, V. (2006) · JAMA · doi:10.1001/jama.295.19.2275 · Cited by 2,468
Phage antibodies: filamentous phage displaying antibody variable domains
McCafferty, J., Griffiths, A. D., Winter, G., & Chiswell, D. J. (1990) · Nature · doi:10.1038/348552a0 · Cited by 2,423
Systematic variation in gene expression patterns in human cancer cell lines
Ross, D. T., Scherf, U., Eisen, M. B., Perou, C. M., Rees, C., Spellman, P., Iyer, V., Jeffrey, S. S., Van de Rijn, M., Waltham, M., et al. (2000) · Nature Genetics · doi:10.1038/73432 · Cited by 2,088
Cited by
Targeting mitochondria for cancer therapy
Fulda, S., Galluzzi, L., & Kroemer, G. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3137 · Cited by 1,629
Size and shape effects in the biodistribution of intravascularly injected particles
Decuzzi, P., Godin, B., Tanaka, T., Lee, S.-Y., Chiappini, C., Liu, X., & Ferrari, M. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.10.014 · Cited by 965
Intravascular Delivery of Particulate Systems: Does Geometry Really Matter?
Decuzzi, P., Pasqualini, R., Arap, W., & Ferrari, M. (2009) · Pharmaceutical Research · doi:10.1007/s11095-008-9697-x · Cited by 616
Self-citationStimuli-Responsive Polymeric Nanocarriers for Drug Delivery, Imaging, and Theragnosis
Das, S. S., Bharadwaj, P., Bilal, M., Barani, M., Rahdar, A., Taboada, P., Bungau, S., & Kyzas, G. Z. (2020) · Polymers · doi:10.3390/polym12061397 · Cited by 581
Phage display and other peptide display technologies
Jaroszewicz, W., Morcinek-Orłowska, J., Pierzynowska, K., Gaffke, L., & Węgrzyn, G. (2022) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuab052 · Cited by 331
Efficient Selection of DARPins with Sub-nanomolar Affinities using SRP Phage Display
Steiner, D., Forrer, P., & Plückthun, A. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.07.085 · Cited by 271
In Vitro Antibody Affinity Maturation Targeting Germline Hotspots
Ho, M., & Pastan, I. (2009) · Methods in Molecular Biology™ · doi:10.1007/978-1-59745-554-1_15 · Cited by 21
“Efforts have been made to improve the affinity of antibodies by random or semi-random mutations (2, 3).”
Background
Metadata
- Authors
- SERGEEVA, A., KOLONIN, M., MOLLDREM, J., PASQUALINI, R., & ARAP, W.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2006-12-30
- Volume
- 58
- Issue
- 15
- Pages
- 1622-1654
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W2060742905
- Cited by
- 266
- References
- 243
- FWCI
- 8.96
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.